Quantum BioPharma (NASDAQ: QNTM) is gaining attention as a biopharmaceutical company with a diversified platform targeting neurodegenerative, metabolic and alcohol misuse disorders. Recently highlighted in a feature article, the company is advancing clinical-stage therapeutics, consumer-focused wellness products, and strategic investments designed to address areas of significant unmet medical need.
The company's strategy combines pharmaceutical research and development with commercialization partnerships and licensing structures intended to support multiple potential revenue streams and long-term growth initiatives. Quantum BioPharma is advancing programs across multiple stages of development while leveraging scientific research, intellectual property, and commercial relationships as part of its broader business strategy.
Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. This positions the company at the forefront of potential treatments for neurodegenerative diseases.
In the consumer wellness space, Quantum invented UNBUZZD and spun out its over-the-counter version to Unbuzzd Wellness Inc., led by industry veterans. Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses. More information about Unbuzzd can be found at www.unbuzzd.com.
The company's diversified approach aims to create multiple revenue streams while addressing significant unmet medical needs. For investors, Quantum BioPharma represents a potential opportunity to participate in a biotech company with both clinical-stage assets and consumer product revenue. The full article discussing Quantum BioPharma can be viewed at https://ibn.fm/JtLc5.
Forward-looking statements in the article involve risks and uncertainties, and actual results may differ materially. These are detailed in the company's filings with the SEC, including the most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
